Following debut disasters: primary vitreoretinal lymphoma

Introduction. Primary vitreoretinal lymphoma (PVRL) is a subtype of lymphoma of immune-privileged organs. Both diagnosis and treatment decisions pose significant challenges for PVRL.

Aim: to present a clinical observation in treating patients with PVRL and possibilities for improving diagnosis and treatment outcomes.

Main Findings. Since 2024, two patients with PVRL, aged 66 and 75 years, have been treated at the National Medical Research Center for Hematology. Modern diagnostic methods based on molecular analysis to detect mutations in the MYD88/ CD79b genes in vitreous fluid were used to establish the diagnosis. A two-stage approach was used for treatment: remission induction using the R-MPV protocol with the addition of lenalidomide and ibrutinib, followed by consolidation auto-HCT in a conditioning regimen according to the “BBC” program. Disease relapses were detected in both patients early after auto-HCT. Thus, for timely diagnosis, it is advisable to implement minimally invasive methods for studying the molecular profile of PVRL. The development of new therapeutic approaches, integrating innovative cell therapy into first-line treatment and the use of thiotepa-based conditioning regimens, is also advisable.

1. White V.A. Understanding and Classification of Ocular Lymphomas. Ocul Oncol Pathol. 2019;08:379–86. DOI: 10.1159/000499845.

2. Coupland S.E., Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol. 2008;36:564–78. DOI: 10.1111/j.1442-9071.2008.01843.x.

3. Karimi S., Daneshvar K. Intraocular Lymphoma: A Review. J Ophthalmic Vis Res. 2025;20:1-23. DOI: 10.18502/jovr.v20.17181.

4. Mercadal S., Alana M., Barcelo M. I., et al. Ocular involvement in patients with primary central- system lymphoma: Analysis of a multicentre study in Spain. Brit J Haem. 2022;197(6):792–5. DOI: 10.1111/bjh.18148.

5. Soussain C., Malaise D., Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021;138(17):1519–34. DOI: 10.1182/blood.2020008235.

6. Tang C., Downie C., Sagoo M.S., et al. An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators. Br J Haematol. 2025;207:123–31. DOI: 10.1111/bjh.20115.

7. Chen X., Hu Y., Su W., et al. Diagnostic value of genetic mutation analysis and mutation profiling of cell-free DNA in intraocular fl uid for vitreoretinal lymphoma. Cancer Commun. 2022;42(11):1217–21. DOI: 10.1002/cac2.12344.

8. Wang S., Zhou S., Gao J., et al. Primary vitreoretinal lymphoma: diagnosis, treatment , and prognosis — a review of current knowledge and future directions. Blood Sci. 2025;7(2):1–9. DOI: 10.1097/BS9.0000000000000233.

9. Kwak J.J., Lee C.S. Molecular diagnosis of vitreoretinal lymphoma. Taiwan J Ophthalmol. 2025;15:236–44. DOI: 10.4103/tjo.TJO-D-24-00052.

10. Fuente M.I. De, Pablo J., Isildinha A., et al. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. Am J Hematol. 2019;94:455–60. DOI: 10.1002/ajh.25414.

11. Mainguy A., Soussain C., Touitou V., et al. High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study. Bone Marrow Transplant. 2024;60(3):297–304. DOI: 10.1038/s41409-024-02477-y.

12. Guan W., Wang L., Peng X. Targeting Bruton ’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-сenter, phase 2 study. Exp Hematol Oncol. 2022;11(1):1–5. DOI: 10.1186/s40164-022-00354-2.

13. Gao J., Lv L., Zhou S., et al. Systemic high-dose MTX and BTK inhibitors in vitreoretinal lymphoma: efficacy and survival analysis. Blood Sci. 2026;3:8(1):1–5. DOI: 10.1097/BS9.0000000000000279.

14. Koroleva D.A., Zvonkov E.E., Shchetsova O.O., et al. Biopsy-free diagnostics of primary diffuse large B-cell lymphoma of the central nervous system. Gematologiya I Transfusiologiya. 2024;69(3):368–83 (In Russian). DOI: 10.35754/0234-5730-2024-69-3-368-383.

15. Cooper E.L., Riker J.L. Malignant Lymphoma of the Uveal Tract. Am J Ophthalmol. 1951; 34(8):1153–8. DOI: 10.1016/0002-9394(51)90691-5.

16. Givner I.G. Malignant Lymphoma with Ocular Involvement. Am J Ophthalmol. 1951;39(1):29–32. DOI: 10.1016/0002-9394(55)92650-7.

17. Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;(36):1720–48. DOI: 10.1038/s41375-022-01620-2.

18. Panova I.E., Gvazava V.G. Mechanisms of immune privilege of the eye and their role in the pathogenesis of non-infectious uveitis. Effectivnaya pharmacoterapiya. 2025;21(6):34–41 (In Russian). DOI: 10.33978/2307-3586-2025-21-6-34-41.

19. Zhang X., Peng X., Liang D., et al. Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients. Eye Vis. 2025;12(20):1–16. DOI: 10.1186/s40662-025-00434-4.

20. Luo J., Yu S., Xu X., et al. Primary Vitreoretinal Lymphoma: A Retrospective Study of 20 Eyes. J Ophthalmol. 2022;2022:1–7. DOI: 10.1155/2022/4522974.

21. Dutta P., Khetan V., Biswas J. Masquerade syndrome: A review of uveitic imposters. Asia Pac J Ophthalmol. 2024;13:2–11. DOI: 10.1016/j.apjo.2024.100054.

22. Sobolewska B., Chee S., Zaguia F., et al. Vitreoretinal Lymphoma. Cancers (Basel). 2021;13(3921):1–23. DOI: 10.3390/cancers13163921.

23. Tang L., Gu C., Zhang P. Intraocular lymphoma. Int J Ophthalmol. 2017;10(8):1301–7. DOI: 10.18240/ijo.2017.08.19.

24. Carbonell D., Mahajan S., Chee S., et al. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocul Immunol Infl amm. 2021;29(3):507–20. DOI: 10.1080/09273948.2021.1878233.

25. Giuffre C., Menean M., Modorati G.M., et al. Primary vitreoretinal lymphoma : recent advances and literature review. Ann Lymphoma. 2020;4(17):20–7. DOI: 10.21037/aol-20-27.

26. Stoyukhina A.S., Korobov E.N., Smolin S.A. Isolated primary vitreoretinal lymphoma (clinical observation). Vestnik ophthalmologii. 2024;140(2):94–101 (In Russian). DOI: 10.17116/oftalma202414002294.

27. Marchese A., Miserocchi E., Giuffre C., et al. Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze. Brit J Ophthalmol. 2019;103:1–4. DOI: 10.1136/bjophthalmol-2018-313491.

28. Гришина Е.Е., Анрюхина О.М. Вторичные (метастатические) ретинальные лимфомы. Офтальмоонкология. 2025;145:61–7. DOI: 10.25276/0235-4160-2025-2S-61-67.

29. Rishi P., Maitra P., Das K., et al. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab. Int Ophthalmol. 2021;8:1–12. DOI: 10.1007/s10792-021-01828-8.

30. Hossein M., Bonyadi J., Ownagh V., et al. Giraffe or leopard spot chorioretinopathy as an outstanding finding : case report and literature review. Int Ophthalmol. 2018;39(6):1405–12. DOI: 10.1007/s10792-018-0948-5.

31. Pishi F., Dols-Marco R., Francis J.H., et al. Advanced OCT Analysis of Biopsyproven Vitreoretinal Lymphoma. Am J Ophthalmol. 2021;238:16–26. DOI: 10.1016/j.ajo.2021.11.023.

32. Ruterhenke T., Jana B., Simon I. Maskierte Bedrohung: das primar vitreoretinale Lymphom (PVRL). Ophthalmologie. 2025;122:716–20. DOI: 10.1007/s00347-025-02228-4.

33. Albadri S.A.M.T., Pulido J.S., Macon W.R., et al. Histologic finfings in vitreoretinal lymphoma. Learning From Enucleation Specimens. Retina. 2020;40(2):391–8. DOI: 10.1097/IAE.0000000000002676.

34. Lee D., Lee J., Nahm J., et al. Diagnostic Accuracy of Vitreous Cytology in Patients with Vitreoretinal Lymphoma. J Clin Med. 2022;11(6450):1–8. DOI: 10.3390/jcm11216450.

35. Chapuy B., Stewart C., Dunford A.J., et al. Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes. Nat Med. 2019;24(5):679–90. DOI: 10.1038/s41591-018-0016-8.

36. Lee J., Kim B., Lee H., et al. Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma. Haematologica. 2020;105:458–60. DOI: 10.3324/haematol.2019.233783.

37. Arai A., Takase H., Yoshimori M., et al. Gene expression profiling of primary vitreoretinal lymphoma. Cancer Sci. 2020;111:1417–21. DOI: 10.1111/cas.14347.

38. Yoshifuji K., Sadato D., Toya T., et al. Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. Haematologica. 2024;109:3641–9. DOI: 10.3324/haematol.2023.284953.

39. Habot-wilner Z. Efficacy and safety of intravitreal methotrexate for vitreoretinal lymphoma — 20 years of experience. Br Soc Haematol. 2021;194(1):92–100. DOI: 10.1111/bjh.17451.

40. Miserocchi E., Ferreri A.J.M., Giuffre C., et al. MYD88 L265P mutation detection in the aqueous humor of patients with vitreoretinal lymphoma. Retina. 2019;39(4):679–84. DOI: 10.1097/IAE.0000000000002319.

41. Hiemcke-Jiwa L.S., Loon N.H. ten D., Leguit R.J., et al. Potential Diagnosis of Vitreoretinal Lymphoma by Detection ofMYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction. JAMA Ophthalmol. 2018;136(10):1–7. DOI: 10.1001/jamaophthalmol.2018.2887.

42. Grimm S.A., Pulido J.S., Jahnke K., et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol. 2007;(18):1851–5. DOI: 10.1093/annonc/mdm340.

43. Beecher M., Rana K., Gowda R., et al. Ophthalmic complications of radiotherapy. Graefes Arch Clin Exp Ophthalmol. 2026;264(3):41351666. DOI: 10.1007/s00417-025-07010-5.

44. Zhou N., Xu X. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma. Springer Nat. 2021;36(7):1448–55. DOI: 10.1038/s41433-021-01657-0.

45. Jiang T., Gu J., Liu S., et al. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate. BMC Ophthalmol. 2022; 22:375:1–9. DOI: 10.1186/s12886-022-02604-7.

46. Hashida N. Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma. Transl Vis Sci Technol. 2012;1(3):1–11. DOI: 10.1167/tvst.1.3.1.

47. Castellino A., Pulido J.S., Johnston P.B., et al. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990–2018. Am J Hematol. 2018;(94):291–8. DOI: 10.1002/ajh.25350.

48. Lam M., Touitou V., Choquet S., et al. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study. Am J Hematol. 2021;96(7):823–33. DOI: 10.1002/ajh.26199.

49. Kaburaki T., Matsuda J., Matsuda I., et al. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Brit J Haematol. 2017;179(2):246–55. DOI: 10.1111/bjh.14848.

50. de Smet M.D., Stark-Vancs V., Kohler D.R., et al. Intraocular Levels of Methotrexate After Intravenous Administration. Am J Ophthalmol. 1996;121(4):442–4. DOI: 10.1016/S0002-9394(14)70444-1.

51. Baumann M.A., Ritch P.S., Hande K.R., et al. Treatment of lntraocular Lymphoma With High-Dose Ara-C. Cancer. 1986;57(7):1273–5.

52. Houillier C., Taillandier L., Dureau S., et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019;37(10):823–33. DOI: 10.1200/JCO.18.00306.

53. Soussain B.C., Suzan F., Hoang-xuan K., et al. Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma. J Clin Oncol. 2001;19(3):742–9. DOI: 10.1200/JCO.2001.19.3.742.

54. Omuro A., Correa D.D., DeAngelis L.M., et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. DOI: 10.1182/blood-2014-10-604561.

55. Zvonkov E.E., Koroleva D.A., Gabeeva N.G., et al. High-dose chemotherapy for primary diffuse large B-cell lymphoma of the central nervous system. Interim results of the “CNS-2015” protocol. Gematologiya I Transfusiologiya. 2019;64(4):447–61 (In Russian). DOI: 10.35754/0234-5730-2019-64-4-447-461.

56. Choquet S., Pivert C., Toutee A., et al. CAR T‐CELL therapy is higly effective in vitreoretinal lymphomas: A LOC network study. Hematol Oncol. 2025;43(S3):195–6. DOI: 10.1002/hon.70094.

57. Godfrey J.K., Gao L., Shouse G., et al. Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma. Blood. 2024;144(4):457–61. DOI: 10.1182/blood.2024024168.

58. Wang W., Chen M., Li J., et al. Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma. Leuk Lymphoma. 2025;66(8):1475–80. DOI: 10.1080/10428194.2025.2484365.